How do you proceed with treatment of a patient with stage IIIB NSCLC who progresses DURING treatment with concurrent weekly carboplatin/paclitaxel and radiation?

Assuming no clinical trial, no actionable mutation, and PD-L1 < 50%, do you consider the patient to be primary refractory to platinum and move to single agent immunotherapy or would you consider chemoimmunotherapy vs nivo/ipi?

2 Answers

Mednet MemberInvited Expert

Medical Oncology · Wexner Medical Center at The Ohio State University

Answered on

I have been looking at this question for a little over a week, and struggling to know how to answer this. The relevant trials for a patient with PDL1 somewhere between 0 and 49% (KEYNOTE-189, KEYNOTE-407, KEYNOTE-042, CheckMate 227, and 9LA) would have excluded patients who received either adjuvant ...

Join for free or sign in to see the full answer

Mednet Member

Medical Oncology · Siri Onclogy and hematology Infusion Service

Answered on

This is a low platinum dose. I would most likely switch to chemo and immunotherapy. I would be concerned about pneumonitis with a combined immunotherapy approach initially with the near use of radiation. If after 2 cycles the response is unsatisfactory, one could try then an ipi, nivo approach.

Join for free or sign in to see the full answer